The impact of emricasan on chronic liver diseases: current data

• Published in: Clinical journal of gastroenterology 2022-04, Vol.15 (2), p.271-285
• Main Authors: Lekakis, Vasileios, Cholongitas, Evangelos
• Format: Article
• Language: English
• Subjects: Abdominal Surgery; Animals; Clinical Review; Colorectal Surgery; Gastroenterology; Hepatology; Humans; Hypertension, Portal - drug therapy; Liver - pathology; Liver Cirrhosis - drug therapy; Medicine; Medicine & Public Health; Pentanoic Acids - pharmacology; Pentanoic Acids - therapeutic use; Surgical Oncology
• ISSN: 1865-7257; 1865-7265
• DOI: 10.1007/s12328-021-01585-2

Immoderate caspase-mediated apoptosis in chronic liver injury is a crucial driver of sustained HSC activation and worsening hepatic inflammation as well as fibrosis, with the ultimate outcome of liver cirrhosis and its consequences. Therefore, the inhibition of hepatocyte apoptosis by caspase cascade blockage may be a promising therapeutic strategy to achieve fibrosis regression in chronic liver diseases. Emricasan is a broad-spectrum, liver-targeted caspase inhibitor with a favorable pharmacokinetic profile, characterized by prolonged retention in the liver and low systemic exposure after oral administration. In animal models, emricasan had a clear intrahepatic anti-apoptotic effect with consequent elimination of circulating pro-inflammatory cytokines and favorable impact in liver fibrogenesis and portal pressure. Even though, this intrahepatic drug effect confirmed in human clinical trials, no clear linkage was emerged with portal hypertension, liver function or liver histology in both non-cirrhotic and cirrhotic patients except from a subgroup of patients with high MELD score (> 15) or severe HVPG (> 16 mmHg). As emricasan treatment appeared safe and well-tolerated, irrespective the severity of liver disease, more studies are required to clarify better these subgroups of patients who may benefit most from this drug.